Paloma Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-840
| Closed | -$407K | – | 158 |
|
|
2025
Q1 | $407K | Buy |
+840
| New | +$391K | 0.05% | 97 |
|
|
2024
Q3 | – | Sell |
-2,700
| Closed | -$1.27M | – | 1709 |
|
|
2024
Q2 | $1.27M | Buy |
+2,700
| New | +$1.17M | 0.04% | 456 |
|
|
2023
Q4 | – | Sell |
-623
| Closed | -$217K | – | 955 |
|
|
2023
Q3 | $217K | Sell |
623
-3,224
| -84% | -$1.13M | 0.01% | 581 |
|
|
2023
Q2 | $1.35M | Buy |
+3,847
| New | +$1.3M | 0.05% | 309 |
|
|
2022
Q2 | – | Sell |
-944
| Closed | -$246K | – | 1787 |
|
|
2022
Q1 | $246K | Buy |
+944
| New | +$224K | 0.01% | 1274 |
|
|
2021
Q4 | – | Sell |
-52,912
| Closed | -$9.6M | – | 2128 |
|
|
2021
Q3 | $9.6M | Buy |
52,912
+15,217
| +40% | +$2.97M | 0.24% | 54 |
|
|
2021
Q2 | $7.6M | Buy |
37,695
+30,237
| +405% | +$6.32M | 0.14% | 124 |
|
|
2021
Q1 | $1.6M | Sell |
7,458
-4,572
| -38% | -$1M | 0.03% | 497 |
|
|
2020
Q4 | $2.84M | Buy |
12,030
+9,833
| +448% | +$2.26M | 0.07% | 287 |
|
|
2020
Q3 | $598K | Buy |
+2,197
| New | +$606K | 0.02% | 1040 |
|
|
2020
Q2 | – | Sell |
-2,400
| Closed | -$571K | – | 2259 |
|
|
2020
Q1 | $571K | Sell |
2,400
-2,450
| -51% | -$562K | 0.03% | 452 |
|
|
2019
Q4 | $1.06M | Buy |
4,850
+2,599
| +115% | +$526K | 0.02% | 920 |
|
|
2019
Q3 | $381K | Buy |
+2,251
| New | +$398K | 0.01% | 1372 |
|
|
2019
Q2 | – | Sell |
-8,127
| Closed | -$1.49M | – | 2218 |
|
|
2019
Q1 | $1.49M | Buy |
+8,127
| New | +$1.5M | 0.04% | 552 |
|
|
2018
Q4 | – | Sell |
-1,305
| Closed | -$252K | – | 1803 |
|
|
2018
Q3 | $252K | Sell |
1,305
-4,785
| -79% | -$852K | ﹤0.01% | 1301 |
|
|
2018
Q2 | $1.03M | Buy |
6,090
+62
| +1% | +$9.61K | 0.02% | 709 |
|
|
2018
Q1 | $982K | Buy |
6,028
+1,010
| +20% | +$165K | 0.02% | 994 |
|
|
2017
Q4 | $752K | Sell |
5,018
-6,105
| -55% | -$904K | 0.01% | 1173 |
|
|
2017
Q3 | $1.69M | Buy |
11,123
+7,800
| +235% | +$1.17M | 0.02% | 853 |
|
|
2017
Q2 | $428K | Sell |
3,323
-12,888
| -80% | -$1.55M | 0.01% | 1637 |
|
|
2017
Q1 | $1.77M | Sell |
16,211
-15,622
| -49% | -$1.38M | 0.02% | 862 |
|
|
2016
Q4 | $2.35M | Buy |
31,833
+21,179
| +199% | +$1.72M | 0.02% | 587 |
|
|
2016
Q3 | $929K | Sell |
10,654
-3,178
| -23% | -$300K | 0.01% | 1080 |
|
|
2016
Q2 | $1.19M | Buy |
13,832
+3,675
| +36% | +$318K | 0.01% | 1038 |
|
|
2016
Q1 | $807K | Buy |
10,157
+6,413
| +171% | +$580K | 0.01% | 1028 |
|
|
2015
Q4 | $471K | Sell |
3,744
-17,766
| -83% | -$2.14M | 0.01% | 1064 |
|
|
2015
Q3 | $2.24M | Buy |
21,510
+15,435
| +254% | +$1.98M | 0.05% | 304 |
|
|
2015
Q2 | $750K | Sell |
6,075
-75,794
| -93% | -$9.55M | 0.01% | 899 |
|
|
2015
Q1 | $9.66M | Sell |
81,869
-4,526
| -5% | -$542K | 0.27% | 62 |
|
|
2014
Q4 | $10.3M | Buy |
86,395
+62,859
| +267% | +$7.08M | 0.44% | 41 |
|
|
2014
Q3 | $2.64M | Sell |
23,536
-3,513
| -13% | -$334K | 0.12% | 169 |
|
|
2014
Q2 | $2.56M | Buy |
27,049
+18,849
| +230% | +$1.32M | 0.11% | 185 |
|
|
2014
Q1 | $580K | Buy |
8,200
+3,570
| +77% | +$283K | 0.04% | 350 |
|
|
2013
Q4 | $344K | Sell |
4,630
-3,370
| -42% | -$235K | 0.02% | 734 |
|
|
2013
Q3 | $607K | Sell |
8,000
-4,591
| -36% | -$365K | 0.02% | 457 |
|
|
2013
Q2 | $1.01M | Buy |
+12,591
| New | +$927K | 0.06% | 263 |
|
Other funds holding VRTX
Paloma Partners's VRTX Position: Q2 2025 in Review
Paloma Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 840 shares — an estimated $407K sold.
Paloma Partners first reported a position in VRTX in Q2 2013 and held it in 36 quarters. The position peaked at $10.3M in Q4 2014. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.
- Paloma Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Paloma Partners sold 840 Vertex Pharmaceuticals shares in Q2 2025, an estimated $407K.
- Paloma Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 36 quarters.
- Paloma Partners's Vertex Pharmaceuticals position peaked at $10.3M in Q4 2014.
- 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.
Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.